Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17031823 | 0.84 | PDE2A (0.43) | PDE2AFFAR4SCN5ACYP3A4KCNH2 | |
| SCHEMBL18899038 | 0.83 | PDE2A (0.40) | PDE2AFFAR4SCN5ACYP3A4KCNH2 | |
| SCHEMBL17033102 | 0.83 | FFAR4 (0.40) | PDE2AFFAR4SCN5ACYP3A4KCNH2 | |
| SCHEMBL17033110 | 0.82 | HSP90AA1 (0.55) | PDE2ATGFBR1PDE10ACCR1CCR8 | |
| SCHEMBL10203124 | 0.77 | XDH (0.52) | KCNH2CCR1CCR8SCN10AGRM5 | |
| SCHEMBL10203331 | 0.76 | SCN10A (0.53) | TGFBR1SCN5ACCR1CCR8SCN10A | |
| SCHEMBL17034407 | 0.76 | FFAR4 (0.48) | PDE2AFFAR4SCN5ACYP3A4KCNH2 | |
| SCHEMBL18313969 | 0.75 | GRM5 (0.43) | TGFBR1KCNH2CCR1CCR8GRM5 | |
| SCHEMBL17033097 | 0.73 | POLB (0.45) | CCR1CCR8 | |
| SCHEMBL17034410 | 0.72 | GRM5 (0.48) | TGFBR1CCR1CCR8HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464956-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9796741-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170298084-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9732104-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9695205-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | PDE2A 4490/4885FFAR4 2142/4885TGFBR1 4009/4885 |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | PDE2A 4092/4885FFAR4 1494/4885TGFBR1 652/4885 |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | PDE2A 2729/4885FFAR4 1752/4885TGFBR1 2245/4885 |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | PDE2A 3049/4885FFAR4 3688/4885TGFBR1 2812/4885 |
| US-20170298084-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | PDE2A 3817/4885FFAR4 1245/4885TGFBR1 1498/4885 |
| US-10464956-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | TFPI, CFD, F3 | PDE2A 4394/4885FFAR4 1552/4885TGFBR1 1005/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | PDE2A 3772/4885FFAR4 2482/4885TGFBR1 1707/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | PDE2A 4361/4885FFAR4 2248/4885TGFBR1 1915/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | PDE2A 4711/4885FFAR4 1120/4885TGFBR1 3167/4885 |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, F3 | PDE2A 4394/4885FFAR4 1552/4885TGFBR1 1005/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | PDE2A 3817/4885FFAR4 1245/4885TGFBR1 1498/4885 |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, CFH | PDE2A 3756/4885FFAR4 361/4885TGFBR1 2174/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | PDE2A 3772/4885FFAR4 2482/4885TGFBR1 1707/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | PDE2A 4361/4885FFAR4 2248/4885TGFBR1 1915/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | PDE2A 3756/4885FFAR4 361/4885TGFBR1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.